$RXST

RxSight (RXST): Millennium entities, Israel Englander report 7.3% ownership stake

RxSight, Inc. said filings show Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander beneficially own 3,030,287 shares, or 7.3% of the common stock class, as of June 30, 2026. The entities report shared voting and dispositive power, with a Joint Filing Agreement dated Aug. 3, 2026.

Original reporting
Published Aug 4, 2026, 11:18 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 5, 2026, 8:37 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefFinancial news
Primary signal
$RXST
Neutral
medium confidence
Mentioned
$RXST
Relevance
4/10
alphai data visualization · based on stocktitan.net
Decision brief

The 30-second read

$RXSTNeutralLow
01

Why it matters

The disclosed stake can raise attention around potential governance influence, but the filing summary provides no explicit plan, demands, or corporate action tied to the ownership.

02

Market read

This is a governance-related datapoint for RXST, but without activist or operational specifics it is unlikely to drive a fundamental repricing by itself.

03

What to watch

Traders may need to monitor subsequent 13D/13G amendments, proxy activity, or board/management engagement to determine whether this stake is activist or purely investment-driven.

Relevance 4/10Novelty 4/10Timing: ownership stake reported as of June 30, 2026, filed via joint agreement dated Aug 3, 2026

Background

The text summarizes a beneficial ownership report showing Millennium Management LLC and Israel A. Englander-related entities holding 7.3% of RxSight’s common stock as of June 30, 2026, under a joint filing agreement dated Aug 3, 2026.

Company-level read

Ticker impact

$RXSTNeutralMedium confidence
Context

RxSight discloses Millennium Management and Israel A. Englander reporting 3,030,287 shares, or 7.3%, beneficial ownership as of June 30, 2026.

Expected impact

Near-term price impact is likely limited unless follow-on filings or actions indicate activism or strategic intent.

Evidence & confidence

The article is a beneficial ownership reporting summary (joint filing) with no stated voting/dispositive control and no additional catalyst beyond the stake percentage.

Market effects

No direct sector read-through because the filing does not describe product, trial, or regulatory developments.

None indicated.

None indicated.

Counterpoint

A reported 7.3% stake may be largely passive and not translate into near-term changes to strategy or capital allocation.

Key entities

  • RxSight, Inc.

    Subject issuer whose common stock beneficial ownership is reported at 7.3% by Millennium and Israel A. Englander-related entities.

  • Millennium Management LLC

    Reporting entity in the beneficial ownership disclosure.

  • Israel A. Englander

    Named individual associated with the reported beneficial ownership stake.

Related articles

$ALCMed

Adjustable precision vision post-cataract surgery

Alcon and RxSight announced a non-exclusive collaboration to develop adjustable presbyopia-correcting intraocular lenses. RxSight’s Light Adjustable Lens is described as FDA-approved and adjustable after surgery via non-invasive light treatments. Alcon will lead global commercialization, RxSight will handle development and manufacturing and receive royalties on net sales.

$RXSTMedAI 8/10

RxSight (RXST) Q2 2026 Earnings Call Transcript

RxSight (RXST) held its Q2 2026 earnings call. The company said it withdrew full-year 2026 guidance and will resume formal guidance in early 2027. Q2 total revenue was $33.7M, including $6.5M from an Alcon collaboration. Product sales were $27.2M, down 19% YoY, with a Q2 net loss of $12.1M.

$RXSTMedAI 8/10

RxSight, Inc. (RXST): Results of Operations and Financial Condition

RxSight, Inc. (RXST) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 rxst-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 RXSIGHT, INC. REPORTS SECOND QUARTER 2026 RESULTS AND PROVIDES UPDATE ON 2026 OUTLOOK Aliso Viejo, Calif. – August 5, 2026 – RxSight, Inc. (NASDAQ: RXST) today reported financial results for the quarter ended June 30, 2026, a

$RXSTMed

RxSight Announces Appointments of Aziz Mottiwala as Chief Executive Officer and Ron Kurtz, M.D. as Chief Medical Officer

RxSight, Inc. (NASDAQ: RXST) announced a leadership transition effective July 20, 2026. Aziz Mottiwala will become President and CEO, succeeding Ron Kurtz, M.D., who will remain Chief Medical Officer. Kurtz will also resign from the board, with Mottiwala appointed in his place. The company cited commercial and clinical continuity around its light adjustable lens technology.

$RXSTMed

RxSight Lands Tarsus Commercial Leader as CEO

RxSight (Nasdaq: RXST) appointed Aziz Mottiwala as CEO on July 15, replacing Dr. Ron Kurtz, who becomes chief medical officer. Mottiwala previously served as Tarsus Pharmaceuticals’ chief commercial officer. RXST shares rose 7.2% to $5.63 after the news. The article cites RXST’s forecast cuts and a Bank of America price target cut to $6.50, plus an Alcon partnership with $60 million upfront and up to $140 million in milestones.

$RXSTMedAI 8/10

RxSight Q2 Sales Sink 20% as Alcon Deal Bolsters 2026 Outlook

RxSight (NASDAQ:RXST) reported Q2 sales of 11 Light Delivery Devices (LDDs) and one LDD rental, lowering sales 20% and leaving an installed base of 1,166 units. Cash, cash equivalents and short-term investments were about $209M. It revised 2026 revenue to $140M-$160M, including $110M-$120M RxSight sales and $30M-$40M Alcon collaboration revenue, and raised gross margin outlook to 73%-75%.